The Federal Trade Commission said it's seeking a resolution with Cigna, the parent company of the pharmacy benefit manager. The agency filed an antitrust complaint against Express Scripts, Optum Rx and CVS Caremark in 2024, alleging the "Big Three" PBMs use anticompetitive tactics to control the insulin supply chain within their vertical.